- Home
- IPA vs BIAF Comparison
IPA vs BIAF Comparison
Compare IPA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- BIAF
- Stock Information
- Founded
- IPA 1983
- BIAF 2014
- Country
- IPA Canada
- BIAF United States
- Employees
- IPA N/A
- BIAF N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IPA Health Care
- BIAF Health Care
- Exchange
- IPA Nasdaq
- BIAF Nasdaq
- Market Cap
- IPA 18.9M
- BIAF 21.4M
- IPO Year
- IPA 2017
- BIAF 2022
- Fundamental
- Price
- IPA $0.44
- BIAF $1.31
- Analyst Decision
- IPA Strong Buy
- BIAF Strong Buy
- Analyst Count
- IPA 2
- BIAF 1
- Target Price
- IPA $6.00
- BIAF $6.00
- AVG Volume (30 Days)
- IPA 1.1M
- BIAF 150.9K
- Earning Date
- IPA 12-12-2024
- BIAF 11-14-2024
- Dividend Yield
- IPA N/A
- BIAF N/A
- EPS Growth
- IPA N/A
- BIAF N/A
- EPS
- IPA N/A
- BIAF N/A
- Revenue
- IPA $17,441,886.00
- BIAF $9,367,785.00
- Revenue This Year
- IPA $4.33
- BIAF $302.41
- Revenue Next Year
- IPA $35.64
- BIAF $15.00
- P/E Ratio
- IPA N/A
- BIAF N/A
- Revenue Growth
- IPA 11.21
- BIAF 2813.87
- 52 Week Low
- IPA $0.35
- BIAF $1.21
- 52 Week High
- IPA $2.60
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- IPA 40.98
- BIAF 40.08
- Support Level
- IPA $0.40
- BIAF $1.21
- Resistance Level
- IPA $0.53
- BIAF $1.37
- Average True Range (ATR)
- IPA 0.07
- BIAF 0.08
- MACD
- IPA 0.00
- BIAF 0.01
- Stochastic Oscillator
- IPA 37.76
- BIAF 45.45
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, Australia and others. The majority of its revenue is derived from United States of America.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.